CSCasey Smiley

Casey Smiley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Casey Smiley has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Updating CMV protocols in lung transplant patients: a single-center case study modeling use of generative AI for antimicrobial stewardship protocol development and economic impact analysis

    by Kyle T. Enriquez, Augusto Dulanto Chiang, Casey Smiley, Milner Staub

    Objective: Antimicrobial Stewardship Programs (ASPs) need healthcare economic analyses to support and inform ASP strategies. This work aimed to determine whether widely available artificial intelligence (AI) platforms like Microsoft Copilot TM could facilitate healthcare economics analyses for ASP programs without dedicated healthcare economic supports. Design: AI (Microsoft Copilot TM ) was prompted to develop a cytomegalovirus prophylaxis protocol for lung transplant recipients using only PubMed-indexed articles. Copilot TM was then prompted to produce probabilistic samples of simulated patients from aggregate statistics of a 165-patient cohort from Vanderbilt University Medical Center and to analyze cost-effectiveness across four distinct cytomegalovirus prophylaxis protocols, including its own. Setting: Tertiary care academic medical center, including outpatient and inpatient environments. Patients or participants: Simulated patient data was developed via random, single-blind, probabilistic selection from pre-defined aggregate cohort statistics. Results: The AI-generated prophylaxis protocol was evidence-based without hallucination, but this conservative protocol relied on outdated evidence and was associated with significant increases in expected per-patient cost (mean +$4740, P < .01) compared to recent guideline-based and institutional protocols. AI independently identified and executed sensitivity analyses, which revealed that in this simplified model, letermovir use had a large impact on expected per-patient cost. Conclusions: The AI-proposed protocol was less cost-effective, but data suggest that careful prompting can provide appropriate PubMed-indexed literature to support ASP protocol development. Additionally, CoPilot TM provided a thorough cost-effectiveness analysis comparing all potential and existing protocols. With appropriate oversight, AI and Microsoft Copilot TM can conduct healthcare economic analyses suitable for ASP strategic planning and implementation.


  • Open Access

    Implementing Updated Intraamniotic Infection Guidelines at a Large Academic Medical Center

    by Casey Smiley, Jessica Rizzuto, Nicola White, Christina Fiske, Jennifer Thompson, Minhua Zhang, Ben Ereshefsky, Milner Staub

    Intraamniotic infection (IAI) affects 2-5% of pregnancies, causing significant neonatal and maternal morbidity. The American College of Obstetrics and Gynecology suggests ampicillin and gentamicin as first line IAI treatment. Due to potential drug toxicity, changes in gentamicin susceptibility cutoff points, and rising Enterobacterales gentamicin and ampicillin resistance, changes in IAI antibiotic treatment were implemented at Vanderbilt University Medical Center. Combination ampicillin, gentamicin and clindamycin were replaced by piperacillin-tazobactam in institutional IAI treatment. Implementation strategies included repeated education sessions to gain stakeholder trust and buy-in and changing pre-existing electronic clinical decision support tools (eCDST) to default selection of piperacillin/tazobactam, capitalizing on highly reliable intervention strategies of forcing function and automatization/computerization. Change in antibiotic use, measured in days of therapy (DOT)/1000 patient days present (1000PDP) by week initiated, before and after eCDST changes was analyzed with interrupted time series analysis. Effects on hospital length of stay, repeat antibiotics within 14 days, and 30-day readmission were evaluated using multivariable linear and logistic regression. After updated eCDST go-live, piperacillin-tazobactam use increased by 1.9 DOT/1000PDP (95% Confidence Interval (CI) 0.7, 3.1) by week initiated and ampicillin, gentamicin, and clindamycin use decreased by -2.5 DOT/1000PDP (95% CI -3.8, -1.2) by week initiated. Hospital length of stay, repeat antibiotics within 14 days, and 30-day readmission rate did not significantly change. Forced function changes to existing eCDSTs, supported by stakeholder education, successfully changed IAI empiric antibiotic use without unintended patient safety consequences.


  • Open Access

    2225. Implementing Updated Intraamniotic Infection Guidelines at a Large Academic Medical Center

    by Casey Smiley, Jessica Rizzuto, Nicola C White, Christina T Fiske, Jennifer Thompson, Benjamin Ereshefsky, Milner Staub

    Pre-existing Intraamniotic Infection Protocol Updated Intraamniotic Infection Protocol Our updated protocol for intraamniotic infection, based off of the local antibiogram. Quality Improvement Barriers and Interventions The inner behavior wheel of change was used to identify barriers to implementation. Interventions were assessed and designed using the hierarchy of intervention effectiveness. The pre-implementation survey had a 49% (61/142) response rate with 75% feeling confident ordering antibiotics for IAI ≥ 75% of the time. However, 52% reported feeling satisfied ≤ 50% of the time with the current antibiotic ordering process. Only 49.2% were aware of internal IAI guidelines. Antibiotic Use in Postpartum and Labor and Delivery Wards January 2020 through April 2023 Days of therapy (DOT) per 1000 patient days present (PDP) for aminoglycosides, ampicillin, and piperacillin-tazobactam in postpartum and labor and delivery wards 1/1/2020 through 4/2023. Cefazolin is shown as a control, as this was not a target of intervention, and remains as a standard pre-operative antibiotic. Clinical decision support tools, an example of forced function interventions, were used for successful implementation of updated antibiotic guidelines for IAI, facilitated by collaboration with stakeholders and widespread education. Further analysis of their long-term impact on antibiotic use and any potential for unintended patient harm are planned. Impact on stakeholders is being assessed via a post-implementation survey. Jennifer Thompson, MD, Up To Date Contributor: Honoraria Milner Staub, MD, MPH, Gilead: Stocks/Bonds|Johnson & Johnson: Stocks/Bonds